COMMUNIQUÉS West-GlobeNewswire

Mesoblast to Present at Upcoming Global Life Sciences Conference in London
05/04/2019
NEW YORK and MELBOURNE, Australia, April 05, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced an upcoming corporate [...]
Curetis to Publish its Full-Year 2018 Financial Results on April 11, 2019
05/04/2019
Company to host earnings conference call on same day Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 5, 2019, 08:00 am CET - Curetis N.V. (the " Company " and, together with its subsidiaries, "Curetis"), a [...]
Enzymatica AB:Notice of annual general meeting 2019 in Enzymatica AB (publ)
05/04/2019
Press release 5 April, 2019 Notice of annual general meeting 2019 in Enzymatica AB (publ) The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the “Company”) are hereby invited to attend the annual general [...]
Professor Linda Carpenter joins Nexstim's Scientific Advisory Board
05/04/2019
Press release, Helsinki, 5 April 2019 at 9.00 am (EET) Professor Linda Carpenter joins Nexstim's Scientific Advisory Board Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and [...]
Genmab Announces Submission of Supplemental New Drug Application in Japan for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
05/04/2019
Media Release Copenhagen, Denmark, April 5, 2019 Supplemental new drug application (sNDA) submitted in Japan for daratumumab in combination with lenalidomide and dexamethasone as treatment for patients newly diagnosed [...]
DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS)
05/04/2019
Montrouge, France, April 5, 2019 DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of [...]
DBV Technologies annonce l’exercice de la totalité de l’option de surallocation consentie dans le cadre de son offre globale d’actions ordinaires pouvant prendre la forme d’American Depositary Shares
05/04/2019
Montrouge, France, le 5 avril (07h30 CEST), 2019 DBV Technologies annonce l’exercice de la totalité de l’option de surallocation consentie dans le cadre de son offre globale d’actions ordinaires pouvant prendre la forme [...]
ESPERITE (ESP) announces private placement of convertible loan notes to the European Select Growth Opportunities Fund
05/04/2019
Amsterdam, The Netherlands – 05 April 2019 Esperite N.V. (Euronext: ESP, “ Esperite ”) announces today a EUR 250,000 private placement of 25 convertible notes with a principal amount of EUR 10,000 each (the “ Notes ”), [...]
Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES
05/04/2019
PRESS RELEASE REGULATED INFORMATION 5 April 2019, 07:00 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 5 April 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular [...]
Zealand Pharma announces Emmanuel Dulac as new CEO
05/04/2019
Company announcement – No. 11 / 2019 Zealand Pharma announces Emmanuel Dulac as new CEO Emmanuel Dulac will join Zealand Pharma as new Chief Executive Officer on April 22, 2019. Emmanuel comes from a position as Chief [...]
AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia
05/04/2019
TOKYO, April 05, 2019 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for treating serious diseases, announced today that they have obtained conditional [...]
Profound Medical Announces Positive Topline Results from TACT Pivotal Clinical Trial of TULSA-PRO® in Patients with Prostate Cancer
05/04/2019
All Primary Efficacy and Safety Endpoints, and Key Secondary Endpoints Achieved TORONTO, April 04, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company [...]
Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
04/04/2019
Company Release no. 07/2019 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 04 April 2019 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis [...]
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2018
04/04/2019
COPENHAGEN, Denmark, April 04, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results [...]
Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/04/2019
BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies [...]
BeyondSpring to Present at the 18th Annual Needham Healthcare Conference
04/04/2019
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a [...]
Axovant Announces Plan to Effect Reverse Share Split
04/04/2019
- Closing of $40 million financing with participation from leading shareholders - - 1-for-8 reverse share split expected in May 2019 - BASEL, Switzerland, April 04, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. ( [...]
Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG
04/04/2019
SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special [...]
Homology Medicines Presents Preclinical Data from PKU Gene Therapy Program Demonstrating Restored Metabolic Pathway and Increased Neurotransmitter Production
04/04/2019
Company Announced IND Clearance Today for Phase 1/2 Clinical Trial BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today preclinical [...]

Pages